Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Insertion of microRNA targets into the flavivirus genome alters its highly neurovirulent phenotype.

Heiss BL, Maximova OA, Pletnev AG.

J Virol. 2011 Feb;85(4):1464-72. doi: 10.1128/JVI.02091-10. Epub 2010 Dec 1.

3.

Evaluation of the Langat/dengue 4 chimeric virus as a live attenuated tick-borne encephalitis vaccine for safety and immunogenicity in healthy adult volunteers.

Wright PF, Ankrah S, Henderson SE, Durbin AP, Speicher J, Whitehead SS, Murphy BR, Pletnev AG.

Vaccine. 2008 Feb 13;26(7):882-90. doi: 10.1016/j.vaccine.2007.12.015. Epub 2008 Jan 4.

4.
6.
7.

Construction and characterization of chimeric tick-borne encephalitis/dengue type 4 viruses.

Pletnev AG, Bray M, Huggins J, Lai CJ.

Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10532-6.

8.
9.

MicroRNA targeting of neurotropic flavivirus: effective control of virus escape and reversion to neurovirulent phenotype.

Heiss BL, Maximova OA, Thach DC, Speicher JM, Pletnev AG.

J Virol. 2012 May;86(10):5647-59. doi: 10.1128/JVI.07125-11. Epub 2012 Mar 14.

10.

Comparison of live and inactivated tick-borne encephalitis virus vaccines for safety, immunogenicity and efficacy in rhesus monkeys.

Rumyantsev AA, Chanock RM, Murphy BR, Pletnev AG.

Vaccine. 2006 Jan 12;24(2):133-43. Epub 2005 Aug 9.

PMID:
16115704
11.

Chimeric Langat/Dengue viruses protect mice from heterologous challenge with the highly virulent strains of tick-borne encephalitis virus.

Pletnev AG, Karganova GG, Dzhivanyan TI, Lashkevich VA, Bray M.

Virology. 2000 Aug 15;274(1):26-31.

12.

The neurovirulence and neuroinvasiveness of chimeric tick-borne encephalitis/dengue virus can be attenuated by introducing defined mutations into the envelope and NS5 protein genes and the 3' non-coding region of the genome.

Engel AR, Rumyantsev AA, Maximova OA, Speicher JM, Heiss B, Murphy BR, Pletnev AG.

Virology. 2010 Sep 15;405(1):243-52. doi: 10.1016/j.virol.2010.06.014. Epub 2010 Jul 1.

13.

Safety evaluation of chimeric Langat/Dengue 4 flavivirus, a live vaccine candidate against tick-borne encephalitis.

Pripuzova NS, Tereshkina NV, Gmyl LV, Dzhivanyan TI, Rumyantsev AA, Romanova LIu, Mustafina AN, Lashkevich VA, Karganova GG.

J Med Virol. 2009 Oct;81(10):1777-85. doi: 10.1002/jmv.21587.

PMID:
19697399
14.
15.

Molecularly engineered live-attenuated chimeric West Nile/dengue virus vaccines protect rhesus monkeys from West Nile virus.

Pletnev AG, Claire MS, Elkins R, Speicher J, Murphy BR, Chanock RM.

Virology. 2003 Sep 15;314(1):190-5.

17.

Recombinant chimeric Japanese encephalitis virus/tick-borne encephalitis virus is attenuated and protective in mice.

Wang HJ, Li XF, Ye Q, Li SH, Deng YQ, Zhao H, Xu YP, Ma J, Qin ED, Qin CF.

Vaccine. 2014 Feb 12;32(8):949-56. doi: 10.1016/j.vaccine.2013.12.050. Epub 2014 Jan 4.

PMID:
24394443
18.

Chimeric West Nile/dengue virus vaccine candidate: preclinical evaluation in mice, geese and monkeys for safety and immunogenicity.

Pletnev AG, Swayne DE, Speicher J, Rumyantsev AA, Murphy BR.

Vaccine. 2006 Sep 29;24(40-41):6392-404. Epub 2006 Jun 21.

PMID:
16831498
19.

Single-dose vaccine against tick-borne encephalitis.

Rumyantsev AA, Goncalvez AP, Giel-Moloney M, Catalan J, Liu Y, Gao QS, Almond J, Kleanthous H, Pugachev KV.

Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):13103-8. doi: 10.1073/pnas.1306245110. Epub 2013 Jul 15.

20.

Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates.

Guirakhoo F, Weltzin R, Chambers TJ, Zhang ZX, Soike K, Ratterree M, Arroyo J, Georgakopoulos K, Catalan J, Monath TP.

J Virol. 2000 Jun;74(12):5477-85.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk